[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100452349":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":19,"locations":27,"responsibleParty":41,"collaborators":10,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":10,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":51,"minAge":52,"maxAge":10,"enrollmentInfo":53,"targetDuration":56,"studyType":57,"phases":10,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":30,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"The University of Hong Kong","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Post-Haematopoietic Stem Cell Transplantation (Post-HSCT) patients",null,"* Patient aged 18 or above\n* Underwent allogeneic HSCT in Queen Mary Hospital(QMH) in the two-year recruitment period",{"label":13,"type":10,"description":14,"interventionNames":10},"Family Control Subjects","The research team will invite an accompanying family member to be the family control. Microbiome and tear samples will be collected for comparison. The sample collection schedule is the same as the corresponding post-HSCT case.",[16],{"name":17,"affiliation":5,"role":18},"Allie Lee","PRINCIPAL_INVESTIGATOR",[20,24],{"name":17,"role":21,"phone":22,"phoneExt":10,"email":23},"CONTACT","+852 39621405","aleeni@hku.hk",{"name":25,"role":21,"phone":10,"phoneExt":10,"email":26},"Alex HS Kan","alexkhs@connect.hku.hk",[28],{"facility":29,"status":30,"city":31,"state":10,"zip":10,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Department of Ophthalmology, LKS Faculty of Medicine, The University of Hong Kong","RECRUITING","Hong Kong","HK",{"type":34,"coordinates":35},"Point",[36,37],114.17469,22.27832,{"lat":37,"lon":36},[40],{"name":17,"role":18,"phone":10,"phoneExt":10,"email":10},{"type":18,"investigatorFullName":17,"investigatorTitle":42,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Clinical Assistant Professor","100452349","ogvhd-after-bone-marrow-transplantation-a-territory-wide-cohort-100452349",false,"NCT05170347","oGVHD After Bone Marrow Transplantation: a Territory-wide Cohort","Ocular Graft-Versus-Host-Disease After Allogeneic Haematopoietic Stem Cell Transplantation: A Territory-Wide Prospective Cohort","Inclusion Criteria:\n\n* Patient aged 18 or above\n* Underwent allogeneic HSCT in QMH in the two-year recruitment period\n\nExclusion Criteria:\n\n* Underwent autologous HSCT\n* Patient unable to attend follow-up visits\n\nFamily Control Subjects The research team will invite an accompanying family member to be the family control. Microbiome and tear samples will be collected for comparison. The sample collection schedule is the same as the corresponding post-HSCT case.",true,"ALL","18 Years",{"count":54,"type":55},500,"ESTIMATED","5 Years","OBSERVATIONAL","Allogeneic Haematopoietic stem cell transplantation (HSCT) is an effective treatment for all array of blood or blood-producing organ disorders. Graft-versus-host-disease (GVHD) occurs as a result of an overactive immunological system against normal host tissues. It can happen in the liver, skin, mucosal surface of the eye, gastrointestinal tract, and genitalia.\n\nOcular GVHD occurs in 30-70% of patients after HSCT. It mainly affects the ocular surface, including the conjunctiva and cornea. In severe cases, multiple clinical manifestations can lead to painful non-healing corneal ulcers, secondary infections, and visual loss.\n\noGVHD can be debilitating and severely impact patients' quality of life. However, there are no widely accepted guidelines available for prevention and management.\n\nIn collaboration with the Department of Haematology of Queen Mary Hospital, the investigators set out to establish a territory-wide cohort of patients receiving HSCT. Primarily, the investigators aim to establish the population-based epidemiology of oGVHD and understand the natural history and the long-term ophthalmic outcomes of oGVHD via this study.",[60,61,62],"Graft Vs Host Disease","Haematological Malignancy","Cancer",[60,64,62,65],"Bone Marrow Transplant","Haematological malignancy","2021-12-09",{"date":68,"type":69},"2021-12-27","ACTUAL",{"date":71,"type":69},"2021-04-30",{"date":73,"type":55},"2028-10",{"name":5,"class":6},1]